COLLEGIUM PHARMACEUTICAL INC (COLL) Forecast, Price Target & Analyst Ratings
NASDAQ:COLL • US19459J1043
37.27 USD
-0.02 (-0.05%)
At close: Mar 9, 2026
37.27 USD
0 (0%)
After Hours: 3/9/2026, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for COLLEGIUM PHARMACEUTICAL INC (COLL).
Forecast Snapshot
Consensus Price Target
$54.74
+ 46.87% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate$1.66
Revenue Estimate192.95M
ChartMill Buy Consensus
81.67%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$54.74
Upside
+ 46.87%
From current price of $37.27 to mean target of $54.74, Based on 12 analyst forecasts
Low
$44.44
Median
$57.12
High
$63.00
Price Target Revisions
1 Month
0.94%
3 Months
14.67%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for COLL. The average price target is 54.74 USD. This implies a price increase of 46.87% is expected in the next year compared to the current price of 37.27.
The average price target has been revised upward by 14.67% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.67%
COLL was analyzed by 12 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about COLL.
In the previous month the buy percentage consensus was at a similar level.
COLL was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-26 | Needham | Maintains | Buy -> Buy |
| 2026-01-09 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-08 | Needham | Maintains | Buy -> Buy |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-11-07 | Truist Securities | Maintains | Buy -> Buy |
| 2025-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-28 | Needham | Reiterate | Buy -> Buy |
| 2025-05-09 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2025-04-09 | Needham | Reiterate | Buy -> Buy |
| 2025-03-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-04 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-01-10 | Needham | Upgrade | Hold -> Buy |
| 2025-01-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-11 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2024-09-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-09 | Needham | Reiterate | Hold |
| 2024-08-09 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-09 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2024-07-30 | Needham | Reiterate | Hold |
| 2024-07-30 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2024-06-07 | Jefferies | Upgrade | Hold -> Buy |
| 2024-05-10 | Needham | Downgrade | Buy -> Hold |
| 2024-05-10 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-04-11 | Needham | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate$1.66
Revenue Estimate192.95M
Revenue Q2Q8.55%
EPS Q2Q11.62%
Number of Analysts8
Next Earnings Revisions
Revenue (1 Month)
0.10%
Revenue (3 Months)
-0.35%
EPS (1 Month)
0.07%
EPS (3 Months)
-5.95%
Next Earnings Summary
COLL is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is 1.66 USD and the consensus revenue estimate is 192.95M USD.
The next earnings revenue estimate has been revised downward by 0.35% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 463.9M 67.53% | 566.767M 22.17% | 631.449M 11.41% | 796.86M 26.20% | 827.92M 3.90% | 760.55M -8.14% | 740.7M -2.61% | 814.13M 9.91% | 849.25M 4.31% | 853.54M 0.51% | 573.75M -32.78% | |
| EBITDA YoY % growth | 203.6M 116.60% | 324.717M 59.49% | 339.055M 4.42% | 464.69M 37.05% | 459.33M -1.15% | 414.24M -9.82% | 406.16M -1.95% | 428.2M 5.43% | 451.76M 5.50% | N/A | N/A | |
| EBIT YoY % growth | 69.4M 176.49% | 175.461M 152.83% | 169.895M -3.17% | 310.97M 83.04% | 355.03M 14.17% | 279.9M -21.16% | 365.77M 30.68% | 409.68M 12.00% | 430.54M 5.09% | N/A | N/A | |
| Operating Margin | 14.96% | 30.96% | 26.91% | 39.02% | 42.88% | 36.80% | 49.38% | 50.32% | 50.70% | N/A | N/A | |
| EPS YoY % growth | 0.56 43.59% | 1.18 110.71% | 6.45 446.61% | 7.62 15.66% | 7.62 2.08% | 6.61 -13.21% | 5.04 -23.69% | 6.24 23.76% | 6.61 5.88% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 1.66 11.62% | 1.85 10.12% | 2.01 -10.56% | 2.07 1.52% |
| Revenue Q2Q % growth | 192.95M 8.55% | 201.68M 7.28% | 209.3M -0.03% | 211.33M 2.86% |
| EBITDA Q2Q % growth | 108.47M 38.62% | 114.54M -22.75% | 125M -46.07% | 130.62M 1.50% |
| EBIT Q2Q % growth | 83.455M 284.82% | 90.944M 159.06% | 89.105M 43.52% | 80.635M -24.44% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-12.23%
EPS Next 5 Year
-2.39%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-2.41%
Revenue Next 5 Year
1.28%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
31.88%
EBIT Next 5 Year
18.85%
COLLEGIUM PHARMACEUTICAL INC / COLL Forecast FAQ
What is the average price target for COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
12 analysts have analysed COLL and the average price target is 54.74 USD. This implies a price increase of 46.87% is expected in the next year compared to the current price of 37.27.
What is the next earnings date for COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) will report earnings on 2026-05-06.
What are the consensus estimates for COLL stock next earnings?
The consensus EPS estimate for the next earnings of COLLEGIUM PHARMACEUTICAL INC (COLL) is 1.66 USD and the consensus revenue estimate is 192.95M USD.
How do analysts rate COLLEGIUM PHARMACEUTICAL INC (COLL)?
The consensus rating for COLLEGIUM PHARMACEUTICAL INC (COLL) is 81.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.